10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance

10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $149 million versus the consensus estimate of $142.5 million.

GUIDANCE:

10x Genomics sees Q4 2025 revenue of $154-158 million, versus the consensus of $151 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat